- Home
- YALA vs IMNM Comparison
YALA vs IMNM Comparison
Compare YALA & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YALA
- IMNM
- Stock Information
- Founded
- YALA 2016
- IMNM 2006
- Country
- YALA United Arab Emirates
- IMNM United States
- Employees
- YALA N/A
- IMNM N/A
- Industry
- YALA Computer Software: Programming Data Processing
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- YALA Technology
- IMNM Health Care
- Exchange
- YALA Nasdaq
- IMNM Nasdaq
- Market Cap
- YALA 645.8M
- IMNM 747.7M
- IPO Year
- YALA 2020
- IMNM 2020
- Fundamental
- Price
- YALA $4.40
- IMNM $9.91
- Analyst Decision
- YALA
- IMNM Strong Buy
- Analyst Count
- YALA 0
- IMNM 5
- Target Price
- YALA N/A
- IMNM $28.60
- AVG Volume (30 Days)
- YALA 197.1K
- IMNM 695.8K
- Earning Date
- YALA 11-11-2024
- IMNM 11-13-2024
- Dividend Yield
- YALA N/A
- IMNM N/A
- EPS Growth
- YALA 31.83
- IMNM N/A
- EPS
- YALA 0.74
- IMNM N/A
- Revenue
- YALA $329,773,319.00
- IMNM $10,129,000.00
- Revenue This Year
- YALA $4.54
- IMNM N/A
- Revenue Next Year
- YALA $13.09
- IMNM N/A
- P/E Ratio
- YALA $5.95
- IMNM N/A
- Revenue Growth
- YALA 5.34
- IMNM N/A
- 52 Week Low
- YALA $3.71
- IMNM $6.93
- 52 Week High
- YALA $6.44
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- YALA 55.37
- IMNM 30.69
- Support Level
- YALA $4.04
- IMNM $12.46
- Resistance Level
- YALA $4.51
- IMNM $13.52
- Average True Range (ATR)
- YALA 0.16
- IMNM 0.85
- MACD
- YALA 0.03
- IMNM -0.15
- Stochastic Oscillator
- YALA 75.83
- IMNM 6.71
About YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.